Company intelligence / Profile preview

Vaxkit

Montréal, QC, Canada

Ownership: Private
Development stage: Other

Overview

Vaxkit Inc. is a veterinary biotechnology company specializing in personalized cancer immunotherapy for companion animals. The company provides an in-clinic kit that enables veterinarians to prepare an autologous vaccine using a patient's own tumor antigens and heat shock proteins. This treatment utilizes a hydroxyapatite-mediated delivery system to stimulate a specific immune response against cancer cells. Marketed as APAVAC in Europe by its manufacturer Hastim, Vaxkit has demonstrated clinical efficacy in improving survival rates for dogs with lymphoma and other solid tumors.

Therapeutic areas: Oncology
Modalities: VaccineAutologous vaccineBiologic
Industry: Veterinary

Partnerships

Hastim

Beyond the preview

Go deeper on Vaxkit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxkit.

Explore the full profile